Vimta Labs Limited files SEBI Takeover Disclosure under Regulation 31(4)
Vimta Labs Limited, a listed testing and analytical laboratory services company, has submitted a formal disclosure to NSE in compliance with Regulation 31(4) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. This disclosure is filed when an acquirer crosses a material shareholding threshold or announces an open offer. The specific parties, consideration, and percentage stake are subject to the detailed disclosure document filed with the exchange.
Why it mattersRegulation 31(4) disclosures are mandatory triggers under the Takeover Code when a threshold acquisition event occurs; the filing flags the deal for regulatory scrutiny and triggers further disclosure and approval milestones.
SectorPharma & Healthcare
[object Object][object Object][object Object][object Object][object Object][object Object][object Object]
Sources
- NSE Corporate Filings (Vimta Labs Disclosure PDF) · official
- SEBI (SAST) Regulations, 2011 – Regulation 31(4) · official
- BSE corporate announcements · official
- NSE corporate announcements · official
- CCI combination orders · official
Related deals
- Anupam Rasayan India acquires controlling stake in Bliss GVS Pharma; Kanga & Co advises sellers28 Oct 2026
- Fortis Healthcare Limited: Press Release28 Oct 2026 · ₹277 Cr
- Fortis Healthcare Limited: Acquisition28 Oct 2026
- ThinkLaw advises Jagsonpal Pharma on acquiring Group Pharma's wellness portfolio27 Oct 2026
- Mankind Pharma Limited: Scheme of Arrangement26 Oct 2026
- Mankind Pharma Limited: Scheme of Arrangement26 Oct 2026